ADREXpharma® can obtain dronabinol via ADREXpharma Identity Kit for the detection of THC, which is an innovative, time-saving method. It enables the pharmacist to detect THC within a few minutes. Dronabinol is subject to the German Narcotics Act and can only be made available in Germany as a prescription drug in accordance with the regulations and monographs of the German Drug Code.
The ADREXpharma Identity Kit for detecting THC is an innovative, time-saving method.
The “Shake & Check” procedure enables the pharmacist to detect THC within a few minutes. This method significantly reduces time and, compared to existing test methods, it is easy to use and has low procurement costs.
ADREXpharma complies with German Narcotics Act
Through ADREXpharma, pharmacies can now also source dronabinol as a starting material for the preparation of prescription and defect drugs that are not subject to approval.
Dronabinol prescription drugs from ADREXpharma are manufactured, tested and approved according to GMP regulations.
The active substance dronabinol is subject to the German Narcotics Act and can only be made available in Germany as a prescription drug in accordance with the regulations and monographs of the German Drug Code (DAC).
Since the slightly yellowish, synthetic oil hardens at a cold temperature and is insoluble in water, it is prepared in the pharmacy by adding oil, such as MCT oil or sesame oil, so that the active substance can be administered in the form of a liquid.
The patient dose is adjusted individually and usually taken orally by drops or capsules (NRF 22.7, 22.8). There is also the possibility of inhalation by evaporation (NRF 22.16).
ADREXpharma to continue specializing in medical cannabis
The current product portfolio consists of starting materials for prescription drugs such as cannabidiol and dronabinol, cannabis flowers, THC extracts, and optional products. The pharmacies are supplied nationwide through pharmaceutical wholesalers.
ADREXpharma® is a medium-sized, independent pharmaceutical company that specializes in the development, manufacture, further development, and marketing of various forms of medical cannabis.
The company based in Koblenz was founded in spring 2018 by Mario Eimuth with two partners from the pharmaceutical industry. It sees itself as the first multi-spectral supplier in the young market of medical cannabis.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in Apotheke Adhoc, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.